Previous 10 | Next 10 |
2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...
2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 2, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 second quarter ended March 31, 2023. Webcast and Conference Call and Details Investors may...
2023-04-16 05:21:00 ET Are you looking for stocks that can make dramatic moves in a short amount of time? If so, you'll want to check out Arrowhead Pharmaceuticals (NASDAQ: ARWR) . SVB Securities, a subsidiary of SVB Financial , recently gave the stock an upgrade to outperform a...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 8.51% on the day to $30.99. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable disease...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 11.02% on the day to $29.12. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseas...
2023-04-12 12:09:05 ET Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) jumped ~11% Wednesday after SVB Securities upgraded the RNAi therapeutics company to Outperform from Market Perform, citing an attractive risk-reward setup following the recent selloff. The analyst Mani Forooh...
2023-04-12 10:03:10 ET Gainers: Altamira Therapeutics ( CYTO ) +74% . Arrowhead Pharmaceuticals ( ARWR ) +11% . Procaps Group ( PROC ) +11% . Tempest Therapeutics ( TPST ) +11% . Meihua International Medical Technologies ( MHUA )...
- Event to include presentations on cardiometabolic, pulmonary, and newly announced central nervous system pipeline programs Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m. ET i...
2023-04-11 07:12:52 ET Summary Arrowhead Pharmaceuticals focuses on developing RNAi therapeutics and has a diverse clinical pipeline and strong industry partnerships. Arrowhead appears undervalued compared to industry counterparts, suggesting potential for increased valuation as i...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...